PhotoMedex Seeks FDA OK of Laser for Atopic Dermatitis

RADNOR, Pa., May 18 -- PhotoMedex Inc. has submitted an application for 510 (k) clearance from the US Food and Drug Administration to commercially market its XTRAC laser system for the treatment of Atopic Dermatitis. Atopic Dermatitis, commonly known as eczema, is a chronic inflammation of the skin that can afflict persons of any age, but is considered to be the most common skin condition in children under the age of 11.





LATEST NEWS

• Liquid Crystal Lens Filters out Light that Causes Seizures
  Nov 26, 2024
• Solar Lasers Could Power Future Space Missions
  Nov 26, 2024
• Optimax Names Joseph Spilman CEO
  Nov 25, 2024
• Shape of a Single Photon Revealed with New Theory
  Nov 25, 2024
• Optogenetics Technique Could Replace Surgical Treatments for Seizures
  Nov 25, 2024
• HOLOEYE Partners with Fraunhofer IPMS on Microdisplay
  Nov 22, 2024
• PI Expands German Production Site: Week in Brief: 11/22/24
  Nov 22, 2024
• Lightsynq Emerges from Stealth with $18M Series A
  Nov 21, 2024